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aBstract
Objective: This study is an updated review of a Southeast Brazilian experience NFPA, emphasizing 
clinical features, laboratorial and imaging assessment, therapeutic management and outcome. De-
sign and Methods: Retrospective study, in which 104 patients with NFPA were evaluated by the 
same team of endocrinologists and neurosurgeon. Patients underwent biochemical evaluation, 
radiological studies and visual field assessment. Results: Hypopituitarism and neuro-ophthalmo-
logical defects were observed in 89%. We observed GH deficiency (81.4%), hypogonadism (63.3%), 
adrenal hypofunction (59.5%), hypothyroidism (20.4%), high (38.5%) and low (16.7%) prolactin le-
vels. Preoperative imaging classified 93% of the tumors as macroadenomas. Extra-sellar expansion 
was observed in 83.8%. Varying degrees of visual disturbance were observed in 74%. Primary treat-
ment was transsphenoidal surgery (75%). Clinical control was achieved with one surgery in 37.5 % 
of patients. The majority of patients needed a second therapeutic approach, radiotherapy or other 
surgeries. Immunohistochemistry resulted negative for pituitary hormones in 43%. Improvement 
of neuro-ophthalmological symptoms was observed in 61% of the patients after treatment. Conclu-
sions: Our data confirm elevated prevalence of mass effect and hypopituitarism in patients har-
boring NFPA. Recurrence due to invasion or incomplete resection of the tumor is quite com-
mon, which frequently leads to a second therapeutic option. Arq Bras endocrinol metab. 2009;53(1):31-39.
Keywords
Pituitary adenomas; hypopituitarism; neuro-ophthalmological defects; extra-sellar expansion; transsphenoidal surgery
resuMo 
Objetivos: Esse estudo é uma revisão atualizada em adenomas hipofisários não-secretores (AHNS), 
enfatizando características clínicas, avaliações laboratorial e neuro-radiológica, manejo terapêutico 
e desfecho. Métodos: Estudo retrospectivo, em que 104 pacientes com AHNS foram avaliados pela 
mesma equipe de endocrinologistas e neurocirurgião. Os pacientes foram submetidos à avaliação 
bioquímica, a estudos radiológicos e à avaliação de campo visual. Resultados: Hipopituitarismo e 
distúrbios neuro-oftalmológicos foram observados em 89%. Observou-se deficiência de GH (81,4%), 
hipogonadismo (63,3%), hipofunção adrenal (59,5%), hipotireoidismo (20,4%), concentrações ele-
vadas (38,5%) e baixas (16,7%) de prolactina. Imagens pré-operatórias classificaram os tumores em 
sua maioria como macroadenomas (93%). Expansão extra-selar foi observada em 83,8%. Graus 
variados de distúrbios visuais foram observados em 74%. O tratamento de escolha foi a cirur-
gia transesfenoidal (75%). O controle clínico foi alcançado com cirurgia em 37,5% dos pacientes. A 
maioria dos pacientes precisou de segunda abordagem terapêutica, radioterapia ou outras cirurgias. 
A imunoistoquímica resultou negativa para hormônios hipofisários em 43%. Melhora de sintomas 
neuro-oftalmológicos foi observada em 61% dos pacientes após o tratamento. Conclusões: Os dados 
do estudo confirmam elevada prevalência de efeitos de massa e hipopituitarismo em pacientes 
com AHNS. Recorrência causada por invasão ou ressecção incompleta do tumor é comum, 
levando frequentemente à segunda opção terapêutica. Arq Bras endocrinol metab. 2009;53(1):31-39.
descritores
Adenomas hipofisários; hipopituitarismo; defeitos neuro-oftalmológicos; expansão extra-selar; cirurgia transesfenoidal
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INTRODUcTION
Pituitary adenomas are common lesions and repre-sent 10 to 20% of all primary brain tumors (1). The-
se tumors can be broadly classified as micro (<10 mm 
diameter) and macroadenomas (>10 mm) and, clinically, as 
functioning and non-functioning adenomas (NFPA), which 
do not secrete biologically active pituitary hormones and 
represent 30% of all pituitary tumors (2). However, ad-
vances in immunoassays, immunohistochemistry, molecu-
lar biology techniques and in vitro studies have allowed 
more detailed characterization of NFPA. Indeed, the 
majority of clinically NFPA can synthesize intact glyco-
protein hormones and/or their free α- and β-subunits. 
Therefore, clinically NFPA can actually be considered 
a diverse group of tumors that also include, besides all 
these glycoprotein hormones, the null cell adenoma and 
oncocytoma (1). 
According to Kovacs and cols. (3), due to the lack of 
hypersecretory endocrine signs and symptoms, the diagno-
sis of NFPA is often delayed and usually presented as a ma-
croadenoma. Clinical manifestations are usually insidious 
and are represented by endocrinological symptoms, such 
as hypopituitarism and prolactin hypersecretion, and neu-
rological symptoms due to mass effects. However, because 
of the increased availability and use of magnetic resonance 
image (MRI), an increasing number of patients have been 
incidentally diagnosed as harboring a pituitary adenoma 
(4,5); about two-thirds of these incidentalomas are micro-
adenomas at diagnosis. Although the NFPA incidentally 
diagnosed can often be followed conservatively, more than 
one-third will show significant growth on serial imaging 
(6,7). On further evaluation, approximately 5% will have 
evidence of visual deficits and around 15% will have some 
degree of pituitary dysfunction (7), indicating that careful 
neurological and endocrinological histories are essential in 
all patients. 
Biochemical diagnosis should be followed by a careful 
screening of the pituitary axis to establish any preoperati-
ve endocrine insufficiency. In addition, diagnosis of NFPA 
preoperatively entails ruling out the secretory syndromes. 
Pituitary mass must be confirmed by imaging studies (8). 
Neuro-ophthalmologic tests include fundoscopy, visual 
field testing and visual acuity.
In the present study, 104 patients harboring NFPA 
were retrospectively assessed in order to present an upda-
ted review of our experience in a primarily tertiary specia-
list referral center, emphasizing clinical feature, laborato-
rial and imaging assessment, therapeutic management and 
outcome.
Patients and Methods
This study was approved by the Ethics Committee for 
the University Hospital of the School of Medicine of 
Ribeirao Preto, University of Sao Paulo. We retrospec-
tively reviewed all 104 patients with NFPA followed at 
the University Hospital between 1990 and 2006. All 
patients were evaluated by the same team of endocrino-
logists and operated on by the same neurosurgeon. All 
patients with NFPA underwent biochemical evaluation 
to confirm the diagnosis of hypopituitarism, radiologi-
cal studies of sella turcica by X-ray, computorized to-
mography (CT) and/or MRI to analyze the mass (size, 
invasion, relation with optic chiasm) and assessment of 
visual field.
Cortisol and testosterone levels were measured by ra-
dioimmunoassay, as previously reported (9). Free thyro-
xin (FT4) and thyroid stimulating hormone (TSH) were 
measured by chemiluminescent method (Immulite, DPC 
Cirrus Inc. Los Angeles, CA). Prolactin (PRL), growth 
hormone (GH), luteinizing hormone (LH), follicle stimu-
lating hormone (FSH), and estradiol levels were measured 
by immunofluorometric (IFMA) assays (DELFIA 80/505 
Wallac Oy, Turku, Finland). IGF-I levels were measured 
by immunoradiometric assay (DSL- Diagnostic Systems 
Laboratories, USA).
Hypothyroidism was diagnosed by basal values of FT4 
and TSH according to the normal age-matched values. On 
the other hand, adrenal, GH, and gonadotrophic deficien-
cies were confirmed by dynamic tests, when appropriate. 
To evaluate the adrenal axis we performed the insulin tole-
rance test (ITT). The GH axis in children was evaluated by 
two dynamic tests, the ITT and L-dopa tests, after priming 
with estrogen. Hypogonadism was diagnosed by the gona-
dotropin releasing hormone (GnRH) test, when patients 
were in an appropriate chronological and bone age. To 
confirm vasopressin deficiency, serum sodium, and plasma 
and urinary osmolality were determined by flame photo-
metry and freezing depression point, respectively. Imaging 
postoperative follow-up was performed 3 to 4 months and 
annually until 5 years after surgery. Adenomas’ tissues were 
investigated by immunohistochemichal staining. Demo-
graphic data were expressed as mean ± SD.
results
clINIcal feaTURes
One hundred and four patients were assessed (62M, 
42F; 87 Caucasian/ 16 African American/ 1 Asian; 
mean age was 47.6±16.1, ranging between 11-81 
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years). Figure 1 shows the distribution of age at diag-
nosis in patients with clinically NFPA. The follow-up 
period (7.4±5.1) ranged from 0-16 years, median of 
6 years. Before diagnosis, duration of symptoms va-
ried from 10 days to 20 years; 95.2% (99/104) of 
patients were symptomatic, in 86.9% the complaints 
were insidious and in 13.1% abrupt (less than 30 
days of symptomatology). Two patients were asymp-
tomatic (1.9%) and in three patients (2.8%) this in-
formation was not available. Hypopituitarism and 
neuro-ophthalmological symptoms were observed in 
91 patients (87.5%); nine patients (8.6%) presented 
only neuro-ophthalmological symptoms while in one 
patient (1%) isolated complaints of hypopituitarism 
were observed (Figure 2).
All clinical manifestations and their frequency are 
represented in Table 1. The most frequent clinical 
manifestations were amenorrhea or menstrual irregu-
larities (78.6%), headache (68.3%), visual field distur-
bance (68.3%), dizziness (40.4%), fatigue or indisposi-
tion (38.4%), drowsiness (35.6%), erectile dysfunction 
(33.9%), dry skin (30.7%), diminished libido (29.9%), 
nausea/vomiting (29.8%), constipation (26.9%), galac-
torrhea (20.2%) and diabetes insipidus (20.2%). Four 
patients presented pituitary adenoma apoplexy symp-
toms at diagnosis, confirmed by image. 
hORmONal aNalysIs
We observed GH deficiency in 81.4%, hypogonadism in 
63.3%, adrenal hypofunction in 59.5%, hypothyroidism 
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figure 1. Age at diagnosis in NfPA patients.
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figure 2. Symptoms at diagnosis in NfPA patients.
table 1. Clinical manifestations of NfPA.
Symptoms Patients (%)
Menstrual irregularities/amenorrhea 78.6
Headache 68.3
Visual field disturbance 68.3
Lack of sexual development 50.0
Dizziness 40.4
Fatigue/indisposition 38.4
Drowsiness 35.6
Erectile dysfunction 33.9
Dry skin 30.7
Diminished libido 29.9
Nausea/vomiting 29.8
Constipation 26.9
Galactorrhea 20.2
Diabetes insipidus 20.2
Orthostatic hypotension 16.3
Weight gain 16.3
Hair rarefaction 15.4
Heat/cold intolerance 11.5
Loss weight 11.5
Loss of consciousness/coma 11.5
Diplopia 10.6
Memory alterations 9.6
Sleep-wake cycle alterations 7.7
Ptosis 6.7
Behavior disturbance 5.8
Irritability 5.7
Feeding behavior alterations 4.8
Paresthesia/tremors 4.8
Voice alterations 2.9
Diarrhea 2.9
Strabismus 2.9
Facial paresthesia 2.9
Ophtalmoplegia 1.9
Deviated walk 1.9
Dementia 0.9
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in 20.4%, hyperprolactinemia in 38.5%, and hypopro-
lactinemia in 16.7% of the tested patients. 
ImagINg fINDINgs
Radiographic images were performed in 95.2% (99/104) 
of individuals before surgery; five patients underwent 
surgery in other services and images were not available. 
Until 1995, 7.7% (n=3) of the patients were evaluated 
by X-ray, 84.6% by CT (n=33) and 7.7% (n=3) by MRI. 
Between 1996 and 2000, 38.9% (n=7) of the patients 
were evaluated by CT and 61.1% (n=11) by MRI; more 
recently, after 2000, 9.5% (n=4) of the patients were 
evaluated by CT and 90.5% (n= 38) performed MRI. 
Based on the available imaging findings, we observed 
93% (92/99) of macroadenomas, 1% (1/99) of microa-
denoma, and in 6% (6/99) of the patients classification 
was not possible, as 3 patients were evaluated only by 
X-ray and 3 patients underwent MRI in other services 
and images were not available. 
Table 2 shows tumor size and its relationship with 
extra-sellar expansion and visual field. Tumor sellar lo-
calization without expansion was observed in 10.1% 
(10/99) of the patients. The majority of patients 
(83/99; 83.8%) presented extra-sellar expansion. Supra-
sellar expansion was observed in 76% (63/83) of pa-
tients; only para-sellar localization in 3.6 % (3/83) of 
patients, and both supra- and para-sellar expansion in 
20.5% (17/83). 
The most common alterations associated with the pre-
sence of the extra-sellar mass were optic chiasmal com-
pression (41%), dorsum sellar alterations and/or erosion 
(33%), sphenoid sinus invasion (16%), cavernous sinus in-
vasion and/or deformation (12%). We also observed third 
ventricle compression (8%), infundibulum dislocation 
(8%), clinoid invasion (7%), pituitary apoplexy (4.8%), hy-
pothalamus compression (6%), supra-sellar cistern invasion 
without chiasmal compression (6%), dorsum sellar invasion 
(5%), ventricle dilatation (2%), sellar wall destruction (2%), 
and supra-tentorial dilatation (2%).
VIsUal fIelD assessmeNT
Visual field was assessed in 94.2% (98/104) of patients, 
26% were normal and 74% presented with varying de-
grees of visual disturbance (Table 2). Six patients had 
no pre-surgery visual field assessment. Among visu-
al disturbances, 28.8% (21/73) presented bitemporal 
hemianopsia (BH), 19.2% (14/73) uni- or bilateral 
amaurosis (AM), 13.7% (10/73) temporal hemianopsia 
(TH), 13.7% (10/73) temporal quadrantanopsia (TQ), 
8.2% (6/73) defects in the superior field (SF), 6.8% 
(5/73) temporal and contralateral nasal hemianopsia 
(TH+NH), 5.5% (4/73) bitemporal hemianopsia and 
nasal hemianopsia (BH+NH), 2.7% (2/73) nasal qua-
drantanopsia (NQ), and 1.4% (1/73) defects in the in-
ferior field (IF).
table 2. NfPA size and its relationship with extra-sellar expansion 
and visual field.
Size 
(mm)
Patients 
(%)
Extra sellar expansion 
(%)
Visual Field 
(%)
0-10 1 None 100 Normal 100
11-20 21.2 Supra sellar 
None
Para sellar
Both
47.7
42.9
4.7
4.7
Normal
TQ
SF
BH
TH 
AM
52.4
19
14.8
4.6
4.6
4.6
21-30 35.3 Supra sellar 
Para sellar
Both
None
77.2
5.7
17.1
0
Normal
TQ 
BH
TH 
SF 
AM
IF
BH+NQ
Unknown 
31.4
17.1
14.9
8.6
8.6
5.7
2.9
2.9
8.6
31-40 19.2 Supra sellar 
Both
Para sellar
None
73.7
26.3
0
0
TH
AM
BH 
BH+NQ
NQ
TH+NH 
Unknown
26.3
26.3
21
10.5
5.3
5.3
5.3
41-50 13.1 Supra sellar 
Both 
Para sellar
None
69.2
30.8
0
0
AM
 BH
TH+NH 
HB+QN
Unknown
30.8
23.1
23.1
7.7
15.3
>50 4.1 Supra sellar 
Both 
Para sellar
None
75
25
0
0
BH
TH+NH
75
25
Ignored 6.1 Unknown 100 BH
AM
TH
TQ
BH+NQ 
33.4
16.7
16.7
16.7
16.7
BH = bilateral hemianopsia; AM = amaurosis; TH = temporal hemianopsia; TH+ NH = 
temporal hemianopsia and nasal hemianopsia; BH+NQ = bitemporal hemianopsia and 
nasal quadrantanopsia; TQ = temporal quadrantanopsia; NQ = nasal quadrantanopsia; 
SF = superior field disturbance; IF = inferior field disturbance.
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Figure 3 shows the relationship between tumor size 
and percentage of visual disturbance. We observed visual 
impairment in 60% and 95% of patients presenting tumors 
larger than 20 and 30mm, respectively. 
figure 3. relationship between tumor size and percentage of 
visual disturbance.
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figure 4. Treatment and outcome of 104 NfPA patients.
TReaTmeNT aND OUTcOme
The first choice treatment was neurosurgery 
performed in 83% (86/104) of the patients. 
Clinical follow-up was the treatment choice in 
13 (12.5%) patients. About 1% was submitted 
to isolated radiotherapy (RTX) and 3.8% refu-
sed to be treated (Figure 4). 
Regarding 13 (12.5%) patients with clinical 
follow-up, 71.4% received hormonal replacement, 
improving hypopituitarism symptoms. Forty six 
percent presented normal visual field, 38.5% had 
a slight loss in visual field, and 15.4% an important 
loss in visual field; this group had no surgery due 
to several associated morbidities. No worsening in 
neuro- ophthalmological symptoms as well as no 
tumor growth was observed during 6.9 years of 
follow-up in these patients. 
Clinical control was defined as improvement of clinical manifestations and complete resection or stabilization of the lesion on neuroradiological imaging. RTX: radiotherapy.
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The transsphenoidal route was performed in 90.7% of 
surgical cases, while the remaining patients (9.3%) were 
treated by the transcranial approach; 33.7% of operated 
patients received adjuvant RTX, indicated due to tumor 
growth. Clinical control was defined as improvement of cli-
nical manifestations and complete resection or stabilization 
of the lesion on neuroradiological imaging after 5 years of 
the surgery, and was achieved in 37.5% of patients after one 
surgery. However, many patients underwent more than one 
therapeutic approach. One surgery and adjuvant RTX were 
performed in 16.3 % of the cases; a second surgery in 10.6% 
and a second surgery with adjuvant RTX in 7.7%; a third 
surgery and RTX in 2.8 % and a fourth surgery and RTX in 
1% of the patients. RTX was indicated during the follow-up 
period after evidence of tumor progression or recurrence. 
The most common transsphenoidal surgical complica-
tion was diabetes insipidus (8.6%). Other transsphenoidal 
surgical complications observed were: cerebrospinal fluid 
leakage (6.7%), ventricular peritoneal derivation (4.8%), 
meningitis (4.8%), sinusitis (3.8%), hydrocephalus (2.9%), 
confusional state (2.9%), anterior hypopituitarism (2.3%), 
ischemic cerebrovascular accident (1.9%), and subarachnoid 
haemorrhage, seizures, cistern haemorrhage, ventriculitis 
and coma in less than 1%, each. Five patients (4.8%) died 
in the immediate post-operative period and the causes were 
subarachnoid haemorrhage and accentuated hydrocephalus; 
ventriculitis; meningitis; septic shock; hyperglycemic coma 
and upper digestive tract haemorrhage. One patient died in 
the late post-operative period from chronic hydrocephalus.
With regard to hormonal replacement in patients with 
hypopituitarism symptoms diagnosed prior to surgical tre-
atment, 70.3% continued receiving hormone replacement 
(35.9% replaced 1 hormonal axis; 34.4%, 2 axes; and 29.7%, 
3 or more axes); only 19.8% improved after surgical treat-
ment and did not need hormone replacement. Sixty one 
percent of the patients experienced improvement of neuro-
ophthalmological symptoms after surgical treatment; 10% 
experienced worsening; in 15% symptoms remained wi-
thout alterations; in 9% of the patients the outcome could 
not be evaluated; and 4.8% died from acute complications. 
Regarding the type of primary or adjuvant RTX, 61.5% 
were conventional, 26.9% conformal RTX, and 11.5 % ra-
diosurgery. Doses of conventional RTX used were 4500 
rads. Complications were observed mainly in patients who 
underwent conventional RTX: cognitive and behavior dys-
functions (22.3%) – such as forgetfulness, mental confusion, 
drowsiness and dementia; tumor necrosis (16.7%); optic 
nerve atrophy (11.2%); anterior hypopituitarism (5.5%); 
cerebral atrophy (5.5%); Parkinson Syndrome (5.5%), and 
hearing disturbance (5.5%). Conformal RTX showed 25% 
(n=2) of cognitive and behavior dysfunctions. So far, no 
complications have been observed on the small number of 
patients (n=3) who underwent radiosurgery.
During the follow-up period of 16 years, 6 patients 
died from other co-morbidities, such as breast cancer (1), 
heart failure (1), and pneumonia (2). In two patients the 
cause of death was not available, since patients did not die 
at our service.
aNaTOmOPaThOlOgy aND ImmUNOhIsTOchemIsTRy
Anatomopathological studies showed in 96.5% of the 
samples, alterations suggestive of tumors, and in 3.6% 
normal pituitary tissue. The analysis of the tissue also 
showed 9.5% of haemorrhagic areas, 8.4% of necrosis 
areas, 1.2% of calcification areas, 1.2% of cholesterol 
crystals areas, 1.2% of cystic areas, and 1.2% of inflam-
matory process.
Immunohistochemistry resulted negative to GH, LH, 
FSH, PRL, ACTH, TSH in 43% of the tested pituitary tis-
sues. Among tumors which were immunopositive for ante-
rior pituitary hormones, we observed mainly glycoprotein 
hormone staining (Table 3). It is important to point out 
that we also observed 9.6% of immunopositivity for ACTH. 
There was no association with immunohistochemistry and 
need of a more aggressive treatment, immediate post ope-
rative complications or death. All these parameters were 
evaluated during a minimal follow-up period of 4.5 years.
table 3. immunohistochemistry of NfPA. 
Immuno-staining Tumors (%)
Negative 43
LH 8
FSH 6.7
PRL 5.4
TSH 5.4
GH 1.4
ACTH 1.4
LH / TSH 5.4
LH / FSH 2.7
LH / PRL 1.4
ACTH / TSH 1.4
ACTH / GH 1.4
ACTH / PRL 1.4
TSH / PRL 1.4
TSH / FSH 1.4
TSH / LH / PRL 2.7
TSH / LH / FSH 1.4
TSH / LH / ACTH 1.4
PRL / FSH / LH 1.4
PRL / FSH / ACTH 1.4
TSH / LH / FSH / GH 1.4
TSH / LH / PRL / ACTH 1.4
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discussion
The relatively low annual incidence of pituitary adeno-
ma diagnosis and long natural history of these tumors 
have hampered efforts to evaluate remote clinical ou-
tcomes in a significant number of patients. Recently, re-
ports from Europe (10) and US (11) have developed an 
evidence-based computerized database, collecting pitui-
tary tumor registry to define features of prognostic sig-
nificance in patients with NFPA. In the present study, in 
order to contribute to the improvement of management 
of these tumors, we show our experience on clinical, 
biochemical, radiological, ophthalmological features, 
treatment and outcome of Brazilian patients with NFPA. 
Data were collected from a primarily tertiary specialist 
referral center, located in Sao Paulo State, in the Sou-
theast region of Brazil. Analysis of our data indicated 
NFPA diagnosis was significantly more frequent in men, 
and almost every patient harbored macroadenomas, in 
accordance to many reports (10,12,13). NFPA were 
mainly diagnosed in the late forties, consistent with the 
pituitary tumor registry in the US (11), but partially in 
contrast to the Italian database (10), which shows that 
NFPA were mainly diagnosed between the fifth and the 
seventh decade. Moreover, 95% of patients were symp-
tomatic, mainly with insidious complaints, and hypopi-
tuitarism and neuro-ophthalmological symptoms were 
observed in 89% of the patients. The three main clini-
cal manifestations were hypogonadism, 78% in women 
and 35% in men, headache in 68% of the patients and 
visual field disturbance in 68% of the patients. In the 
Italian database (10), as well as in the US registry (11), 
about half of the patients presented with mass-related 
symptoms, such as visual defects, headache, and hypo-
gonadism symptoms. As suggested by these authors, 
the signs might still be underestimated or not correctly 
diagnosed and continue to represent a challenge for en-
docrinologists, gynecologists, andrologists, ophthalmo-
logists, and, particularly, for general practitioners. The 
findings in this Brazilian series indicate that prevalence 
of symptoms at diagnosis is larger than in the Italian and 
US series, suggesting that the delay between symptom 
onset and diagnosis is even greater in Brazil, a develo-
ping country. 
Our data also show GH deficiency, hypogonadism and 
adrenal hypofunction in the majority of tested patients. We 
observed almost 40% of hyperprolactinemia related to stalk 
deafferentation, which is in agreement to the frequency re-
ported (42–65%) in other studies (10,11,14). One fifth of 
the patients presented with hypothyroidism, consistent with 
the Italian experience and other studies (10,15,16) and hy-
poprolactinemia was observed in 16.7% of the patients. Of 
particular importance is the detection of cortisol deficiency 
before thyroid deficiency treatment; failure to establish this 
diagnosis preoperatively can have dire consequences.
Macroadenomas with extra-sellar expansion were pre-
sent in the majority of patients at diagnosis, mainly as 
supra-sellar invasion. Due to no clinical hypersecretory 
syndrome of NFPA, patients usually present a large mass 
at diagnosis; MRI is necessary not only for a good deli-
neation of the size and extension of these tumors but also 
to demonstrate residual tumor and tumor regrowth, situ-
ations in which post-operative radiotherapy could be an 
indication (17,18).
Visual field alterations were observed in the majority 
of patients (74%) and showed a wide spectrum of defects, 
while chiasmal compression on imaging was observed only 
in 41% of patients. This discrepancy can be ascribed by the 
poor quality of imaging in the 90’s. The classical bi-tempo-
ral field defect was the most common presentation in our 
study, followed by uni- or bilateral amaurosis. Fields with 
no typical diagnostic pattern were seen in nearly one tenth 
of the patients. These data are partially in contrast to an In-
dian prospective study (19), which showed atypical visual 
field pattern in 20% of the patients. In other series, such no 
typical field constitutes 4.7% of the cases (20). 
In our series, the first choice treatment was neurosur-
gery (83%); transsphenoidal route was performed in 90.7% 
of the surgical cases, while the remaining patients were tre-
ated by the transcranial approach. Clinical control, defined 
as improvement of clinical manifestations and complete 
resection or stabilization of the lesion on neuroradiologi-
cal imaging, was achieved in 37.5% of the patients after 
one surgery. Indeed, our results related to the success of 
surgery treatment are similar to others’ results (10,11), 
suggesting that surgery in NFPA is almost never curative, 
probably due to advanced tumor expansion and invasion 
of neighboring structures. In the absence of good serum 
markers for residual tumor, the decision on further inter-
vention relies mainly on sequential postoperative imaging 
(21). Since residual cells retain their inherent ability to 
proliferate, some tumors continue growing; thus, the indi-
cation of a second therapeutic option is usually necessary. 
One fifth of the patients in the present study underwent a 
second surgery and another fifth were submitted to adju-
vant RTX. In exceptional situations, a third or even four-
th surgery associated to RTX was performed in order to 
achieve clinical control.
The failure of surgical treatment lead to frequent indi-
cation for RTX that was performed in more than one third 
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of the patients in our series. However, the role of RTX in 
pituitary tumor management remains controversial. Al-
though its efficacy remnants, in particular, if administered 
during postoperative period (12,13,22), it has been clearly 
demonstrated that RTX may cause several side effects (23-
25). In accordance to these findings, our series showed high 
percentage of complications after usual doses of conventio-
nal RTX, due to the size of tumors and also probably to 
management of conventional RTX. We observed worsening 
of anterior hypopituitarism in almost one third of the pa-
tients who underwent surgery and adjuvant RTX, cognitive 
and behavior dysfunctions in one fourth, tumor necrosis in 
one fifth, besides other lesions in the central nervous system. 
New radiation techniques, such as Gamma Knife radiosur-
gery, have shown good efficacy in controlling tumor growth 
and a more favorable profile of side effects than the conven-
tional fractionated RTX (26,27). In this Brazilian series, few 
patients underwent radiosurgery, with no observed impor-
tant side effects. It is important to point out that the radio-
surgery technique is supported by insufficient data, due to 
short-term follow-up studies (26,27). 
Because hypopituitarism was an important finding at 
the diagnosis of NFPA in our series (almost 90%), persis-
tent diabetes insipidus and hypopituitarism occurred as a 
treatment complication only in 8.6% and 3.5% respectively, 
which were smaller than the prevalence observed in the 
US registry (11) - 32% and 12%, respectively. With regard 
to hormonal replacement in patients with hypopituitarism 
symptoms diagnosed prior to surgical treatment, the ma-
jority continued receiving hormone replacement, but one 
fifth of the patients improved after surgical treatment and 
did not need hormone replacement. Indeed, this finding 
reinforces data only recently reported that impaired pitui-
tary function could be restored and could even be nor-
malized or improved by selective surgical resection of the 
adenomas in 30% of cases (28,29).
Post-surgical improvement in visual field defects occur-
red in 61% of the cases. These results are similar to other 
series (30,31), but studies have described visual field im-
provement even in 80% of the cases (32); the extent of 
visual impairment recovery is mainly dependent on the 
preoperative visual deficit, which emphasizes the need for 
early intervention in these patients. 
Regarding mortality in the immediate post-operative 
period, our series indicate a total rate of 4.8%, in accordan-
ce with other studies (33,34). However, better patient ou-
tcome after transsphenoidal pituitary tumor surgery, about 
1% or less of death, has been demonstrated in modern se-
ries (35,36). It is important to point out that, among the 
five immediate post-operative deaths, 3 patients harbored 
giant adenomas (diameter equal to or greater than 50mm). 
However, in the present study, only one patient died in 
the immediate post-operative period from complications 
inherent to surgery; other deaths occurred mainly due to 
infectious causes (ventriculitis; meningitis; septic shock) or 
metabolic disturbances. Therefore, our data reflect results 
from a specialized practice setting, in a developing coun-
try where all transsphenoidal pituitary surgeries were 
performed by only one specialist surgeon (37).
Immunostaining of NFPA may be negative for any pi-
tuitary hormone. Alternatively, according to Wilson and 
cols. (38), NFPA may be positive for various anterior pi-
tuitary hormones, most commonly a subunit - β-FSH, 
β-LH or β -HCG or less frequently ACTH, TSH, GH or 
PRL. Turner and cols. (12) observed 35.4% of 65 NFPA 
were gonadotrophin immunopositive and 29.2% were 
immunonegative for all pituitary hormones. Our data, in 
accordance to this study, showed that 43% of tumors were 
immunonegative and more than one fourth were positive 
for gonadotrophin. It is important to point out that, in 
our series, almost 10% of NFPA showed immunoreactivity 
for ACTH, similar to previous data (12). Other studies 
suggested that NFPA immunopositive for ACTH do not 
recur more often than ACTH immunonegative; however, 
when they regrow they show a more aggressive course 
(39,40). 
In conclusion, data collected in this Brazilian series give 
a complete overview of patients with NFPA, concerning cli-
nical features, therapeutic approaches, and long term outco-
mes. This study demonstrates the need to reduce the delay 
between symptom onset and diagnosis of NFPA in a develo-
ping country. Our data as well as the US and Italian studies, 
confirm that predictors of pituitary tumor recurrence and 
markers of persistent disease activity still have to be identi-
fied in order to improve therapeutic guidelines and overall 
cost-effectiveness in the long-term management of NFPA.
Disclosure: No potential conflict of interest to this article was re-
ported. 
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